Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm^3
Brief Summary: The purpose of this study is to determine the best time to begin anti-HIV treatment in individuals who have HIV and tuberculosis (TB).

Study hypothesis: Immediate antiretroviral therapy (ART), initiated after approximately 2 weeks of TB treatment, will reduce the frequency of other AIDS-defining illnesses and death in HIV-infected participants being treated for TB by at least 40% at week 48 when compared to deferred ART, initiated at after 8-12 weeks of TB treatment.


Options:
A: Inclusion Criteria:

* HIV infection documented by a positive HIV antibody test at enrollment;
* Adult men and women (age\>18);
* Cryptococcal meningitis infection documented by a positive CSF CRAG or CSF identification of C. neoformans.
* Place of residence is located within a 50km radius of Harare.

Exclusion Criteria:

* Previous diagnosis (\>1 week) of and treatment for cryptococcal meningitis
* Currently on ARVs, or have been intermittently on and off ART in the past.
* Concurrent use of medications that affect the metabolism of fluconazole e.g., antiseizure medications, oral hypoglycaemic agents.
* History of cardiac failure and or predisposition to arrhythmias will be excluded.
* They are pregnant or active lactation women
* History of active hepatitis or hepatic or renal dysfunction will be excluded.
B: Inclusion Criteria:

* HIV-infected
* Received pre- and post-test counseling at the GHESKIO Centers
* CD4 count between 200 and 350 cells/mm3
* World Health Organization (WHO) Stage I, II, or III HIV disease
* Willing to use acceptable forms of contraception

Exclusion Criteria:

* WHO Stage IV HIV disease (AIDS)
* 7 or more days of cumulative ART prior to study entry OR on ART at time of study entry
* Active TB, if diagnostic work-up for TB is incomplete OR if decision to treat TB has not been made. More information on this criterion can be found in the protocol.
* Recurrent active TB OR history of interrupted or incomplete TB therapy. More information on this criterion can be found in the protocol.
* Has not been evaluated for latent TB and decision to treat latent TB with isoniazid has not been made. More information on this criterion can be found in the protocol.
* Requires ART in the next 3 months, in the opinion of the investigator
* Other serious medical illness requiring chronic maintenance therapy (e.g., hypertension, diabetes) UNLESS the individual has completed at least 14 days of therapy prior to study enrollment AND is clinically stable
* Any psychological condition (e.g., severe depression, schizophrenia) that, in the opinion of the investigator, may interfere with the study
* Any social condition (e.g., pending emigration, pending incarceration) that, in the opinion of the investigator, may interfere with the study
* Active drug or alcohol use that, in the opinion of the investigator, may interfere with the study
* Current inflammation of the pancreas
* Allergy/sensitivity to any of study drugs or their formulations
* Requires certain medications
* Enrolled in another therapeutic or interventional clinical trial
* Pregnant or breastfeeding
C: Inclusion Criteria:

* Age ≥18 years;
* Ability and willingness of participant to give written informed consent;
* CD4 cell count \</=500 cells/mm3
* WHO stage 1 or 2 disease as defined by the following conditions: Asymptomatic; Persistent generalized lymphadenopathy; Moderate unexplained weight loss (under 10% of presumed or measured body weight); Recurrent upper respiratory tract infections (sinusitis, tonsillitis, otitis media, pharyngitis); Herpes zoster; Angular cheilitis; Recurrent oral ulcerations; Papular pruritic eruptions; Seborrheic dermatitis; Fungal nail infections

Exclusion Criteria:

* Any use of ART in the past;
* Pregnancy or breastfeeding at the screening visit;
* Psychologically unprepared to start ART, based on ART readiness survey;
* Plans to transfer care to another clinic during the study period;
* WHO stage 3 or 4 disease.

Note: For the sub-study that includes patients with WHO stage 1 or 2 disease and CD4 count \>500, the inclusion and exclusion criteria are the same; only CD4 count is different.
D: Inclusion Criteria:

* HIV-infected.
* Confirmed or probable TB (more information on the criterion can be found in the protocol).
* Chest x-ray within 30 days prior to study entry.
* Receipt of 1-14 cumulative days of rifampin- or other rifamycin-based TB treatment that was initiated within 28 days prior to study entry.
* CD4 count less than 250 cells/mm\^3 within 30 days prior to study entry.
* Willing to use acceptable methods of contraception while on study drugs and for 6 weeks after stopping these drugs.
* Able to swallow oral medications.
* Parent of guardian willing to provide informed consent, if applicable.
* Karnofsky performance score =\>20 at time of study entry.

Exclusion Criteria:

* ART for longer than 7 cumulative days prior to study entry or treatment for any period of time with one or more antiretrovirals. Participants who have taken ART during pregnancy or for occupational exposure are not excluded.
* Allergy or sensitivity to any of the study drugs or their formulations.
* History of multidrug-resistant TB.
* Receipt of any investigational therapy or chemotherapy within 30 days prior to study entry.
* Certain medications.
* Breastfeeding.

Answer: D